US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Versartis

7.14

0.0000

Volume:- -

Turnover:- -

Market Cap:43.13M

PE:-6.81

High:7.14

Open:7.14

Low:7.14

Close:7.14

52wk High:7.14

52wk Low:1.14

Shares:6.04M

Float Shares:6.04M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.0488

EPS(LYR):-2.4123

ROE:--

ROA:--

PB:0.63

PE(LYR):-2.96

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Versartis

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.versartis.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. The company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 3 clinical trials for the treatment of growth hormone deficiency. It develops drug candidates that it has licensed from Amunix Operating, Inc. The company was founded in 2008 and is headquartered in Menlo Park, California.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/VSAR/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VSAR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VSAR\",,,,,undefined,":{"symbol":"VSAR","market":"US","secType":"STK","nameCN":"Versartis","latestPrice":7.14,"timestamp":1539633599999,"preClose":7.14,"halted":8,"volume":0,"delay":0,"floatShares":6040109,"shares":6040109,"eps":-1.048764,"marketStatus":"Trading","change":0,"latestTime":"12-22 14:12:43 EST","open":7.14,"high":7.14,"low":7.14,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.048764,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766437200000},"marketStatusCode":2,"symbolChange":{"newSymbol":"ARAV","executeDate":"2018-10-16"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":7.14,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VSAR\",,,,,undefined,":{"symbol":"VSAR","floatShares":6040109,"roa":"--","roe":"--","lyrEps":-2.412257,"shares":6040109,"dividePrice":0,"high":7.14,"amplitude":0,"preClose":7.14,"low":7.14,"week52Low":1.14,"pbRate":"0.63","week52High":7.14,"institutionHeld":0,"latestPrice":7.14,"eps":-1.048764,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.048764,"open":7.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VSAR\",params:#limit:5,,,undefined,":[{"date":"2018-10-16","symbol":"VSAR","newSymbol":"ARAV","type":"symbolChange","dateTimestamp":1539662400000},{"market":"US","date":"2018-08-07","symbol":"VSAR","fiscalQuarterEnding":"2018/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1533614400000,"reportTimeType":"","actualEps":-0.27},{"market":"US","date":"2018-05-08","symbol":"VSAR","fiscalQuarterEnding":"2018/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1525752000000,"reportTimeType":"","actualEps":-0.25},{"market":"US","date":"2018-03-01","symbol":"VSAR","fiscalQuarterEnding":"2017/12","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1519880400000,"reportTimeType":"","actualEps":0.87},{"market":"US","date":"2017-10-26","symbol":"VSAR","fiscalQuarterEnding":"2017/09","expectedEps":-0.68,"name":null,"time":"","type":"earning","dateTimestamp":1508990400000,"reportTimeType":"","actualEps":-1.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VSAR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VSAR\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.versartis.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. The company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 3 clinical trials for the treatment of growth hormone deficiency. It develops drug candidates that it has licensed from Amunix Operating, Inc. The company was founded in 2008 and is headquartered in Menlo Park, California.","exchange":"NASDAQ","name":"Versartis","nameEN":"Versartis"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"VSAR\",market:\"US\",,,undefined,":null}}